neomycin oral hepatic encephalopathy
Selected indexed studies
- Hepatic Encephalopathy. (Am J Gastroenterol, 2001) [PMID:11467622]
- Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. (World J Gastroenterol, 2012) [PMID:22371636]
- Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety. (Rev Gastroenterol Disord, 2005) [PMID:15976747]
_Worker-drafted node — pending editorial review._
Connections
neomycin oral hepatic encephalopathy is a side effect of
Sources
- Hepatic Encephalopathy. (2001) pubmed
- Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. (2012) pubmed
- Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety. (2005) pubmed
- Branched-chain amino acids for people with hepatic encephalopathy. (2015) pubmed
- Branched-chain amino acids for people with hepatic encephalopathy. (2017) pubmed
- Alcoholic hepatitis. (2009) pubmed
- Complications of cirrhosis III. Hepatic encephalopathy. (2000) pubmed
- Severe recurrent hepatic encephalopathy that responded to oral branched chain amino acids. (1996) pubmed
- Branched-chain amino acids for people with hepatic encephalopathy. (2015) pubmed
- Erythromycin versus neomycin in the treatment of hepatic encephalopathy in cirrhosis: a randomized double-blind study. (2013) pubmed